RFC1 Natural History Study for Ataxia

RFC1 Natural History Study

Recruiting Observational Study
Ataxia
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
150 (estimated)
Sponsor
Prof. Dr. Matthis Synofzik · Other
Who this trial is looking for

This trial is looking for individuals with a specific genetic condition related to ataxia, as well as healthy people without neurological issues. Participants will help us understand the disease better by providing data and biological samples.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have a genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1.
  • I am a healthy control without signs of neurological or psychiatric disease.
  • I can give written informed consent.
  • I am willing and able to follow study procedures.

You may not be able to join if

  • I have not provided informed consent.
  • I have signs of neuropathy or neurodegenerative disease.
  • I have a movement disorder.
  • I am unable to give informed consent.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This international, multi-center, multi-modal and prospective observational study aims to determine the phenotypic spectrum and the natural progression of the RFC1 repeat expansion disease, and to seek and validate digital, imaging, and molecular biomarkers that aid in diagnosis and serve as outcome measures in future clinical trials of this novel, but frequent ataxia with late adult-onset.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * RFC1: genetic diagnosis of bi-allelic pathogenic repeat expansions in RFC1 * Unrelated healthy controls: no signs or history of neurological or psychiatric disease AND * Written informed consent AND * Participants are willing and able to comply with study procedures Exclusion…
Contacts

Matthis Synofzik, Prof. Dr.

+49 7071 29

matthis.synofzik@uni-tuebingen.de

CONTACT

Andreas Traschütz, Dr. Dr.

+49 7071 29

andreas.traschuetz@uni-tuebingen.de

CONTACT